

## LE GINECO À L'ESMO 2020 !

### GYNECOLOGICAL ORAL SESSION

**IMagyn050**

21 septembre à 16h20

LBA31

### GYNECOLOGICAL MINI ORAL SESSION

**TAPAZ**

Abstract # 808MO

**PAOLA-1 – PFS2**

Abstract# LBA33

**PAOLA-1 – Response rate**

Abstract # 812MO

**PRIMA – PRO**

Abstract # 810MO

**SOLO1 – Follow-up (5 years)**

Abstract# 811MO

**SOLO2 – Subsequent therapies**

Abstract # 813MO

**CA-125 KELIM**

Abstract # 815MO

**DESKTOPIII – Time to first subsequent therapy**

Abstract # 816MO

### SARS- Cov-2 and cancer MINI ORAL SESSION

**THE GCO -002 CACOVID -19 cohort**

Abstract # 1673MO

### GYNECOLOGICAL e-POSTER SESSION

**RETROLA**

Abstract # 823P

**REGOVAR**

Abstract # 829P

### BREAST e-POSTER SESSION

**PADA-1**

Abstract # 304P

## ORAL PRESENTATION : GYNECOLOGICAL CANCER

### **IMagyn 050** Kathleen Moore - LBA31

*Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)*

## GYNECOLOGICAL MINI ORAL SESSION

### **TAPAZ**

#### **Florence Joly - Abstract #808MO**

*Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study*

### **PAOLA-1**

#### **Antonio Gonzales Martin - Abstract #LBA33**

*Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the Phase III PAOLA-1/ENGOT-ov25 trial*

### **PAOLA-1**

#### **Nicoletta Colombo – Abstract #812MO**

*Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial*

### **PRIMA**

#### **Bhavana Pothuri – Abstract #810MO**

*Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial*

### **SOLO1**

#### **Susana Banerjee – Abstract #811MO**

*Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA (BRCAm): 5-year (y) follow-up (f/u) from SOLO1*

### **SOLO2**

#### **J-Sébastien Frenel – Abstract #813MO**

*Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial*

### **CA125 KELIM**

#### **Benoît You – Abstract #815MO**

*The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients*

### **DESKTOPIII**

#### **Fabrice Lécuru – Abstract #816MO**

*AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)*

## SARS-Cov-2 and cancer MINI ORAL SESSION

### **GCO-CACOVD**

#### **Astrid Lièvre – Abstract #1673MO**

*The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management*

## POSTER : GYNECOLOGICAL CANCER END BREAST CANCER

### **RETROLA**

#### **Thibault de la Motte Rouge - Abstract #823P**

*Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study.*

### **REGOVAR**

#### **Olivier Trédan - Abstract #829P**

*Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO Randomized II trial*

### **PADA-1**

#### **J-Sébastien Frenel – Abstract #304P**

*ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial*